The information contained in these releases was current on the date the releases were issued and will become outdated over time. Lilly does not assume any responsibility for updating information in these releases.
Releases
 |
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Nov 18, 2009
|
11.2 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardi...
|
|
Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
12.6 KB |
|
| |
ORLANDO, Florida, Nov 15, 2009 (PR Newswire Europe via COMTEX News Network) -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
14.6 KB |
|
| |
ORLANDO, Fla., Nov 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Nov 2, 2009
|
15.0 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Nov 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA(R) (exenatide) injection.
"The FDA update issued today aligns ...
|
|
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Oct 30, 2009
|
15.8 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA(R) (exenatide) injection. BYETTA is now approved for use as a st...
|
|
Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
Sep 24, 2009
|
15.3 KB |
|
| |
SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass., Sept 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study ...
|
|
Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
Sep 21, 2009
|
15.5 KB |
|
| |
INDIANAPOLIS, Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supp...
|
|
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta®
Sep 11, 2009
|
14.8 KB |
|
| |
INDIANAPOLIS, Sept 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- In the news release, New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R), issued 11-Sep-2009 by Eli Lilly and Company over PR Newswire, the third paragraph, third sentence should read "A total of 18 patients in the study discontinued...
|
|
Know Fibro Initiative Commemorates National Pain Awareness Month
Sep 8, 2009
|
10.0 KB |
|
| |
INDIANAPOLIS, Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- For people living with painful conditions, September is a time for their true stories of triumph to emerge. Helping to foster support and communication, National Pain Awareness Month allows people with painful conditions to educate others about their experiences, build co...
|
|
Effient(TM) is Now Available in Pharmacies
Aug 5, 2009
|
10.0 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States, Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced today.
The U.S. Food and Drug Administration approved Effient tablets o...
|
|
Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
Jul 27, 2009
|
12.7 KB |
|
| |
INDIANAPOLIS, July 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company continues to lead the way in advancing lung cancer treatment. On the heels of new FDA and European Commission approvals for ALIMTA((R)) (pemetrexed for injection) as a treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance s...
|
|
/C O R R E C T I O N -- Eli Lilly and Company/
Jul 23, 2009
|
22.3 KB |
|
| |
INDIANAPOLIS, July 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Today, Eli Lilly and
Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)
has approved a new use for its osteoporosis drug FORTEO(R) [teriparatide (rDNA
origin) injection] to treat osteoporosis associated with sustained, systemic
glucocortico...
|
|
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
Jul 20, 2009
|
17.6 KB |
|
| |
SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass., Jul 20, 2009 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes,
Inc. (Nasdaq: ALKS) today announced positive results from a study
comparing subjects randomized to either exenatide once weekly or Lantus(R)
(insuli...
|
|
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
Jul 10, 2009
|
14.6 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, July 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient(TM) (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in ...
|
|
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Jul 10, 2009
|
16.2 KB |
|
| |
INDIANAPOLIS, July 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for maintenance treatment of patients with other than predominantly squamous cell histology in locally-ad...
|
|
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Jul 7, 2009
|
14.3 KB |
|
| |
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and...
|
|
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Jul 6, 2009
|
17.3 KB |
|
| |
INDIANAPOLIS, July 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) announced today it received a fourth approval from the U.S. Food and Drug Administration (FDA) for ALIMTA(R) (pemetrexed for injection). The latest approval is for ALIMTA as a maintenance therapy for locally advanced or metastatic non-sma...
|
|
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
Jun 10, 2009
|
18.0 KB |
|
| |
ADELPHI, Md., June 10, 2009 /PRNewswire via COMTEX News Network/ -- ADELPHI, Md., June 10 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia o...
|
|
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Jun 9, 2009
|
13.9 KB |
|
| |
SILVER SPRING, Md. and INDIANAPOLIS, June 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and impro...
|
|
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Jun 8, 2009
|
16.0 KB |
|
| |
NEW ORLEANS, June 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a meta-analysis of cardiovascular (CV) events that showed no increased risk of CV events associated with BYETTA(R) (exenatide) injection use compared to a pooled c...
|
|
|
